Cosmo is a specialty pharmaceutical company focused in treating selected Gastrointestinal Disorders. Discover more about our strategic approaches.
The company is developing a range of pharmaceutical products that are based on new chemical entities and are targeted on skin diseases that can be topically treated.
Inflammatory Bowel Diseases (IBD) are a group of chronic, progressive, recurring and debilitating disorders characterized by severe damage of the gastro-intestinal tract.
Cosmo reports growth in product revenues and progress in late stage product and corporate development
PAION GRANTS COSMO PHARMACEUTICALS REMIMAZOLAM LICENSE IN THE U.S. AND COSMO BECOMES LARGEST SHAREHOLDER OF PAION AG
Cosmo announces European approval of Eleview™
Read all news articles
Cosmo is a specialty pharmaceutical company that aims to become a global leader in the market of optimized therapies for selected gastro-intestinal diseases. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for gastro-intestinal diseases.
Read more about us
Share price information
20/09/2016 - 21/09/2016
Get in touch with us today.
© 2016 Cosmo pharmaceuticals